Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm By: Benzinga via Benzinga May 03, 2016 at 08:42 AM EDT Biogen Inc. (NASDAQ: BIIB) revealed its intension to spin off its hemophilia business as an independent, publicly traded firm. ... Read More >> Related Stocks: Biogen Idec